CY2076B1 - N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives - Google Patents

N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives

Info

Publication number
CY2076B1
CY2076B1 CY9802076A CY9802076A CY2076B1 CY 2076 B1 CY2076 B1 CY 2076B1 CY 9802076 A CY9802076 A CY 9802076A CY 9802076 A CY9802076 A CY 9802076A CY 2076 B1 CY2076 B1 CY 2076B1
Authority
CY
Cyprus
Prior art keywords
ylacyl
pyrrolo
pyrimidin
glutamic acid
acid derivatives
Prior art date
Application number
CY9802076A
Other languages
English (en)
Original Assignee
Univ Princeton
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2076(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/528,155 external-priority patent/US5028608A/en
Application filed by Univ Princeton, Lilly Co Eli filed Critical Univ Princeton
Publication of CY2076B1 publication Critical patent/CY2076B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY9802076A 1989-12-11 1998-09-11 N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives CY2076B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44874289A 1989-12-11 1989-12-11
US47965590A 1990-02-08 1990-02-08
US07/528,155 US5028608A (en) 1989-12-11 1990-05-24 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US07/528,805 US4996206A (en) 1989-12-11 1990-05-24 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives

Publications (1)

Publication Number Publication Date
CY2076B1 true CY2076B1 (en) 1998-09-11

Family

ID=27503964

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802076A CY2076B1 (en) 1989-12-11 1998-09-11 N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives

Country Status (22)

Country Link
EP (1) EP0432677B1 (de)
JP (1) JP3016876B2 (de)
CN (1) CN1030608C (de)
AR (1) AR245129A1 (de)
AT (1) ATE135007T1 (de)
AU (1) AU640182B2 (de)
CA (1) CA2031890C (de)
CY (1) CY2076B1 (de)
DE (2) DE69025723T2 (de)
DK (1) DK0432677T3 (de)
ES (1) ES2084639T4 (de)
GR (1) GR3019784T3 (de)
HK (1) HK1000920A1 (de)
HU (1) HU218483B (de)
IE (1) IE904445A1 (de)
IL (1) IL96531A (de)
LU (1) LU91147I2 (de)
NL (1) NL300181I2 (de)
NZ (1) NZ236385A (de)
PT (1) PT96140B (de)
RU (1) RU2057131C9 (de)
SG (1) SG48098A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254687A (en) 1991-12-04 1993-10-19 The Trustees Of Princeton University Process for the preparation of pyrrolo[2,3-d]pyrimidines
US5235053A (en) * 1992-06-22 1993-08-10 Eli Lilly And Company Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CN100344615C (zh) * 2004-11-25 2007-10-24 重庆医药工业研究院有限责任公司 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
US8629152B2 (en) 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
TWI374886B (en) 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
EP2270013A1 (de) 2006-08-14 2011-01-05 Sicor, Inc. Kristalline Formen von Pemetrexed-Disäure und Herstellungsverfahren dafür
KR20090052355A (ko) 2006-08-14 2009-05-25 시코르, 인크. 순도가 높은 페메트렉세드 이산 및 이의 제조 방법
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
AU2015210337B2 (en) * 2008-06-06 2017-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical combination
NZ588957A (en) * 2008-06-06 2013-03-28 Boehringer Ingelheim Int Pharmaceutical combination of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
WO2011064256A1 (en) 2009-11-24 2011-06-03 Azad Pharmaceutical Ingredients Ag A new crystalline form of pemetrexed disodium
SI2854768T1 (sl) 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Farmacevtski sestavki pemetrekseda
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
EP2997031A1 (de) 2013-05-17 2016-03-23 Instytut Farmaceutyczny Verfahren zur herstellung von hochreinem amorphem pemetrexed-dinatrium und kristallinen formen von n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutaminsäure
EP3008064B1 (de) 2013-06-14 2017-11-22 Synthon B.V. Stabile argininsalze von pemetrexed und zusammensetzungen davon
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
US20180235969A1 (en) 2014-10-16 2018-08-23 Synthon B.V. Liquid pharmaceutical composition comprising pemetrexed
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2019046612A1 (en) * 2017-08-31 2019-03-07 Duquesne University Of The Holy Spirit INHIBITORS OF FIRST-CATEGORY SHMT2 AND MTHFD2 AS ANTI-TUMOR AGENTS
CN110305137A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305134B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305135B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305136A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives

Also Published As

Publication number Publication date
AR245129A1 (es) 1993-12-30
EP0432677A1 (de) 1991-06-19
JPH083166A (ja) 1996-01-09
RU2057131C1 (ru) 1996-03-27
IL96531A0 (en) 1991-09-16
HUT58335A (en) 1992-02-28
PT96140A (pt) 1991-09-30
GR3019784T3 (en) 1996-07-31
DE69025723T2 (de) 1996-10-31
DE69025723D1 (de) 1996-04-11
AU640182B2 (en) 1993-08-19
NZ236385A (en) 1992-05-26
JP3016876B2 (ja) 2000-03-06
NL300181I1 (nl) 2005-05-02
CN1030608C (zh) 1996-01-03
DK0432677T3 (da) 1996-04-09
IE904445A1 (en) 1991-06-19
DE122005000012I2 (de) 2006-02-09
NL300181I2 (nl) 2005-06-01
CA2031890C (en) 2000-07-25
DE122005000012I1 (de) 2005-06-23
PT96140B (pt) 1997-06-30
HU908147D0 (en) 1991-06-28
HU218483B (hu) 2000-09-28
CN1055182A (zh) 1991-10-09
SG48098A1 (en) 1998-04-17
IL96531A (en) 1995-08-31
ATE135007T1 (de) 1996-03-15
ES2084639T3 (es) 1996-05-16
HK1000920A1 (en) 1998-05-08
EP0432677B1 (de) 1996-03-06
RU2057131C9 (ru) 2006-04-10
LU91147I2 (fr) 2005-05-17
ES2084639T4 (es) 2013-06-11
AU6779190A (en) 1991-06-13
CA2031890A1 (en) 1991-06-12

Similar Documents

Publication Publication Date Title
CY2076B1 (en) N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives
ZA909631B (en) N-(pyrrolo(2,3,-d)pyrimidin-3-ylacyl)-glutamic acid derivatives
ZA902185B (en) Amino acid derivatives
EP0416373A3 (en) Amino acid derivatives
EG19674A (en) Antiviral tetrahydroimidazol (1,4) denzodiazepin -2-thiones
ZA893714B (en) N-(5,6,7,8-tetrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)glutamic acid derivatives
ZA902444B (en) Amino acid derivatives
PH25509A (en) DIASTEREOISOMERIC TETRAHYDROPYRIDO (2,3-d)PYRIMIDINE DERIVATIVES, PROCESS THEREOF
ZA893569B (en) 1,1-dioxo-cephem-4-carbothiolic acid derivatives
GB9027494D0 (en) Imidazo(4,5c)pyridines as antiosteoporotic agents
GB8921635D0 (en) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
ZA902395B (en) Amino acid derivatives
AP9000205A0 (en) Antiviral tetrahydroimidazo(1,4)benzodia-zepines
GB8909277D0 (en) 3-alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
ZA903999B (en) Mevinic acid derivatives
ZA907585B (en) Amino acid derivatives
IE871498L (en) PYRRIDAZINO (4,5:3,4) PYRROLO (2,1-a) ISOQUINOLINES
GB8920354D0 (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-thiones
GB8904108D0 (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-thiones
GB8918937D0 (en) Acid derivatives
ZA908085B (en) Imidazole-hept-6-enoic acid derivatives
ZA902133B (en) Acrylamido-penicillanic acid derivatives
IE893838L (en) ß-AMINOBORONIC ACID DERIVATIVES
IE851649L (en) PYRROLO (1,2-b) TRIAZEPINE
IE892083L (en) Amino acid derivatives.